Patents by Inventor Craig C. Malbon

Craig C. Malbon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense oligonucleotides for mitogen-activated protein kinases as therapy for cancer
    Patent number: 6271210
    Abstract: A method is disclosed for inhibiting malignant neoplastic growth of epithelial or endothelial cells in a mammal by administering to the mammal an effective amount of an oligonucleotide complementary to at least a portion of mRNA for ERK-1 or ERK-2 that is overexpressed in the mammal. The antisense oligonucleotides are administered to the mammal as a dosage unit. A method of identifying and monitoring potentially malignant neoplastic cell growth in a mammal is also disclosed.
    Type: Grant
    Filed: October 5, 1999
    Date of Patent: August 7, 2001
    Assignee: The Research Foundation of SUNY
    Inventors: Vimala S. Sivaraman, Hsien-yu Wang, Craig C. Malbon
  • Antisense DNA constructs for expression of hybrid mRNAs driven by inducible, tissue-specific promoters
    Patent number: 6133245
    Abstract: A gene is regulated by introducing into a cell an inducible, tissue-specific antisense DNA construct. The antisense DNA construct comprises any inducible, tissue-specific gene, into which a DNA sequence antisense to any DNA sequence of the gene targeted for regulation has been inserted. The inducible, tissue-specific antisense DNA construct transcribes a hybrid messenger RNA containing an RNA sequence antisense to a sequence of the messenger RNA of the gene targeted for regulation. The hybrid messenger RNA also contains the RNA sequence of the inducible, tissue-specific gene. Some examples of suitable inducible genes include those selected from the group consisting of mammalian cytosolic phosphoenolpyruvate carboxykinase (PEPCK) (GTP, EC 4.1.1.32), mammalian atrial natriuretic factor (ANF), and mammalian alpha myosin heavy chain (.alpha.-MHC). In a preferred embodiment, the inducible, tissue-specific gene is the rat PEPCK gene.
    Type: Grant
    Filed: June 12, 1998
    Date of Patent: October 17, 2000
    Assignee: The Research Foundation of State University of New York
    Inventors: Craig C. Malbon, Christopher M. Moxham
  • Antisense oligonucleotides for mitogen-activated protein kinases as therapy for cancer
    Patent number: 6007991
    Abstract: A method is disclosed for inhibiting malignant neoplastic growth of epithelial or endothelial cells in a mammal by administering to the mammal an effective amount of an oligonucleotide complementary to at least a portion of mRNA for ERK-1 or ERK-2 that is overexpressed in the mammal. The antisense oligonucleotides are administered to the mammal as a dosage unit. A method of identifying and monitoring potentially malignant neoplastic cell growth in a mammal is also disclosed.
    Type: Grant
    Filed: August 12, 1997
    Date of Patent: December 28, 1999
    Assignee: The Research Foundation of SUNY
    Inventors: Vimala S. Sivaraman, Hsien-yu Wang, Craig C. Malbon
  • Antisense DNA constructs for expression of hybrid MRNAs driven by inducible, tissue-specific promoters
    Patent number: 5858774
    Abstract: A gene is regulated by introducing into a cell an inducible, tissue-specific antisense DNA construct. The antisense DNA construct comprises any inducible, tissue-specific gene, into which a DNA sequence antisense to any DNA sequence of the gene targeted for regulation has been inserted. The inducible, tissue-specific antisense DNA construct transcribes a hybrid messenger RNA containing an RNA sequence antisense to a sequence of the messenger RNA of the gene targeted for regulation. The hybrid messenger RNA also contains the RNA sequence of the inducible, tissue-specific gene. Some examples of suitable inducible genes include those selected from the group consisting of mammalian cytosolic phosphoenolpyruvate carboxykinase (PEPCK) (GTP, EC 4.1.1.32), mammalian atrial natriuretic factor (ANF), and mammalian alpha myosin heavy chain (.alpha.-MHC). In a preferred embodiment, the inducible, tissue-specific gene is the rat PEPCK gene.
    Type: Grant
    Filed: October 16, 1995
    Date of Patent: January 12, 1999
    Assignee: The Research Foundation of State University of New York
    Inventors: Craig C. Malbon, Christopher M. Moxham